Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
147 hedge funds and large institutions have $1.56B invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 58 increasing their positions, 54 reducing their positions, and 31 closing their positions.
57% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $7.33M
7% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 54
12% less funds holding
Funds holding: 167 → 147 (-20)
20% less capital invested
Capital invested by funds: $1.94B → $1.56B (-$379M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
65% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$74.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$40.2M |
| 3 |
DM
Deerfield Management
New York
|
+$31.6M |
| 4 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$21.2M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$20.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$75M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$30.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.1M |
| 4 |
CCM
Consonance Capital Management
New York
|
-$23.5M |
| 5 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$20M |
DCPH Hedge Fund Activity: Q2 2021 in Review
147 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2021, worth a combined $1.56B — down 20% from $1.94B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of DCPH and 11 opened new positions — a net loss of 20 holders — while 54 trimmed existing stakes and 58 added.
The largest buyer was OrbiMed, adding an estimated $74.2M. The largest seller was AllianceBernstein, cutting an estimated $75M.
- 147 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2021, down from 167 in Q1 2021.
- Funds reported $1.56B of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2021, down 20% quarter-over-quarter.
- 11 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2021 and 31 closed out, a net change of -20 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q2 2021 was OrbiMed, an estimated $74.2M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2021 was AllianceBernstein, an estimated $75M sold.
Based on aggregated 13F filings for Q2 2021.